Form 4: Theravance Biopharma Insider Tax Withholding Transaction

SVP and General Counsel Brett A. Grimaud disposed of 8,829 shares to satisfy tax obligations related to restricted stock unit vesting.

Summary

• Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, Inc., reported a transaction involving 8,829 ordinary shares.
• The transaction occurred on May 20, 2026, at a price of $16.55 per share.
• The disposal was a mandatory tax withholding event related to the vesting of previously granted restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 363,120 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related transaction rather than a strategic shift or market-driven sale.

Positives

• The transaction was a non-discretionary event required to satisfy tax obligations, rather than an open-market sale.
• The reporting person retains a significant equity stake of 363,120 shares in the company.

Negatives

• The transaction resulted in a reduction of the reporting person's direct share ownership.

Risks

• None identified; this is a routine administrative filing regarding tax withholding.

Future Outlook

Not applicable; this is a historical record of an insider transaction.

Industry Context

StockSavvy.ai notes that tax withholding filings are standard administrative procedures for executives in the biopharmaceutical sector and do not typically signal a change in management sentiment or company outlook.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity compensation plans in the U.S. biotech industry.
• The use of 'sell-to-cover' or share withholding is a common mechanism for executives to manage tax liabilities upon RSU vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax withholding event.

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Transaction, Form 4, Tax Withholding, Equity Vesting